{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Study Assessments\u00b9', 'Screen\u00b9', 'Notes', 'Disease Evaluation', '(i.e., if CT scan was used as baseline, participant needs to be followed by CT scans). Plasmacytoma measurements should be', 'Beta2 microglobulin', 'taken from the CT portion of the PET/CT, or MRI scans, or dedicated CT scans where applicable. For participants with skin only', 'Skeletal survey11', 'involvement, skin lesions should be measured with a ruler. Measurement of tumor size will be determined by the Sum of the', 'Imaging for Extramedullary', 'Products of the maximal perpendicular diameters of measured lesions (SPD). Imaging will be collected for independent review.', 'X', 'disease12', 'For sites in Germany: Only MRI is allowed to be used as imaging modality for participants with extramedullary disease.', 'UPEP (Urine Protein', '13. Only required for participants with IgD/E myeloma, where serum m-component cannot be followed otherwise.', 'Electrophoresis) 24 hr. urine', 'X', 'collection', '14. FISH testing at least for: t (4;14), t (14;16), and 17p13del. FISH results from samples taken within 60 days prior to first dose are', 'Urine immunofixation', 'X', 'acceptable. If testing cannot be performed at a local lab, a bone marrow aspirate can be sent to central lab for analysis. If the', 'SPEP (Serum Protein', 'patient is known to have high risk disease from previous FISH tests regardless of timing (i.e.: t(4;14), or t(14;16) they should be', 'Electrophoresis)', 'stratified as High Risk for the purpose of enrollment.', 'Serum Immunofixation', '15. Minimal residual disease (MRD) to be performed by the central lab at screening, at the time of first achieving VGPR or CR,', 'repeat', 'Serum Kappa, Lambda free', 'MRD testing 6 mo and 12 mo after achieving VGPR or CR (provided VGPR/CR is maintained).', 'Light chain, FLC ratio', 'Calcium corrected for albumin', '16. Bone Marrow (aspirate preferred) for disease assessment performed within the screening period prior to first dose is acceptable.', '(serum)', 'lgG, IgM, IgA', 'X', 'lgD/E13', 'X', 'Bone Marrow (BM) Aspiration/Biopsy', 'BM for FISH 14', 'BM aspirate for BCMA IHC', 'assessment', 'BM for MRD testing15', 'X', 'BM for disease assessment16', 'Health Outcomes', 'PRO-CTCAE', 'NEI-VFQ-25', 'OSDI', 'X', 'BM = bone marrow; BNP = B-type natriuretic peptide; BP = blood pressure; C1D1 = Cycle 1 Day 1, etc. CRP = C-reactive protein; FISH = fluorescence in situ hybridization; FLC = free', 'light chain; HR= heart rate; lg = immunoglobulin; NEI-VFQ-25 = National Eye Institute Visual Functioning Questionnaire 25; OSDI = Ocular Surface Disease Index; PRO-CTCAE =', 'Patient Reported Outcome version of the Common Term Criteria for Adverse Events; PD = Progressive Disease; SPEP = serum protein electrophoresis; UPEP = urine protein', 'electrophoresis.', '22']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 2', 'Schedule of Activities - On Study Assessments', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Wk 42 to be', 'Cycle 2-', 'Cycle 1,', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 1\u00b9', '3 Day', '3, Day', 'performed', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Physical Exam', 'X', 'X', '(Important: Every participant will complete Cycle 1 Day 1 on study assessments. Then, they', \"will complete 'Q3W' assessments starting at week 4' AND the 'Cycle 2-CX with dosing'\", 'Adverse Events3', 'Ongoing', 'Ongoing', 'Ongoing', 'assessments during the treatment phase). If dosing is not completed only perform the', 'Concomitant', 'Medications', 'Ongoing', 'Ongoing', 'Ongoing', '\"Q3W starting at Week 4\" assessments at the scheduled visit.', 'Safety', '1. Assessments scheduled on days of dosing must be done prior to drug administration, unless', 'Ocular Exam4', 'X', 'otherwise specified. All other assessments can be done +3 days unless otherwise specified.', 'ECOG Performance', 'X', '2.', 'GSK2857916 will be administered intravenously on Day 1 (D1) of every 21-day cycle (Q3W)', 'Status', 'until disease progression, unacceptable toxicity, death or withdrawal of consent.', 'Vital Signs (BP, HR,', 'Body', 'X', 'X', '3.', 'All related SAEs are to be collected from consent through os follow-up', 'Temperature)5,', '4.', 'On-study ophthalmic exams to be performed by an ophthalmologist (or an optometrist if an', 'Weight', 'Weight', 'Weight5', 'ophthalmologist is not available) predose every 3 weeks. See Section 9.2.9 for the list of', 'Only', 'Only', 'ophthalmic exam procedures. If there are no corneal signs per the GSK Scale for corneal', 'Hematology7', 'X', 'X', 'events at time of the cycle 4 exam, participants may have their ophthalmologic exams', 'Clinical chemistry7', 'X', 'X', 'decreased to once every 3 months. If a participant subsequently develops ocular symptoms,', 'the participant should be evaluated by an ophthalmologist (an optometrist if an ophthalmologist', 'Urine Dipstick 7', 'X', 'X', 'is', 'not available). Intraocular pressure must be monitored if steroid eye drops are used', 'eGFR (by MDRD', 'continuously for more than 7 days. Additional exams may be performed by the', 'formula- see', 'X', 'X', 'ophthalmologist (an optometrist if an ophthalmologist is not available), as clinically indicated. At', 'Appendix 10)', 'selected sites, participants will undergo additional ophthalmic exams. If you are a selected site,', 'Spot urine for', 'see Section 9.2.9 for full list of ocular sub-study exam procedures.', 'albumin/creatinine', 'X', 'X', 'ratio5, 7,8', '5.', \"If a participant's GSK2857916 dose is not administered at a given visit, the following activities\", 'CRP', 'X', 'do not need to be performed at that visit unless clinically indicated: Vitals, weight, spot urine,', 'Pregnancy Test 5, 9', 'X', 'pregnancy test, ECG, PK sample, ADA sample, and soluble BCMA sample.', 'ECHO', 'As clinically', '6.', 'On initial (first infusion) dosing day, vital signs must be assessed at pre-dose (within 30', 'indicated', 'minutes prior to start of infusion(SOI)) +10 minutes after SOI, within +5 minutes of end of', '12-lead ECG 5,10', 'X', 'X', 'X', '23']\n\n###\n\n", "completion": "END"}